Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RC18 (Telitacicept/Taiai) in moderate-to-severe rheumatoid arthritis with inadequate response to TNF-alpha antagonists
CTR20160250Phase 2Suspended
- Sponsor
- RemeGen
- Start
- May 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in rheumatoid arthritis (RA), sponsored by RemeGen. Started May 2016; status: suspended.
02
Drugs
telitacicept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20160250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160250.